Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

European drug regulator backs mixing COVID-19 vaccines

The European Union drug regulator has given its backing to mixing different types of vaccines in initial vaccination and booster campaigns to battle the coronavirus

Via AP news wire
Tuesday 07 December 2021 07:32 EST
Virus Outbreak France
Virus Outbreak France (Copyright 2021 The Associated Press. All rights reserved)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

The European Union drug regulator gave its backing Tuesday to mixing different types of vaccines in initial vaccination and booster campaigns to battle the coronavirus.

The European Medicines Agency said in a statement that using different types of vaccines together, known as heterologous vaccination, can provide protection against COVID-19.

The announcement comes as much of Europe is facing rising infection and hospital rates and concerns about the new omicron variant.

The EMA, together with the European Center for Disease Control, said that a mix-and-match strategy could give nations more options in vaccination campaigns as much of the continent faces rising infection and hospitalization rates.

“The evidence available so far with different types of authorized vaccines indicates that a heterologous booster appears as good as or better in terms of immune responses than a homologous booster,” the agencies said in a statement.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in